This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Sager, M. A. Articles by La Rue, A. Search for Related Content PubMed PubMed Citation Articles by Sager, M. A. Articles by La Rue, A. Social Bookmarking                         What's this?

Middle-Aged Children of Persons With Alzheimer’s Disease: APOE Genotypes and Cognitive Function in the Wisconsin Registry for Alzheimer’s Prevention

Wisconsin Alzheimer’s Institute, Department of Medicine, University of Wisconsin-Madison, masager{at}wisc.edu

Bruce Hermann, PhD

Wisconsin Alzheimer’s Institute, Department of Medicine, Department of Neurology, University of Wisconsin-Madison

Asenath La Rue, PhD

Wisconsin Alzheimer’s Institute, Department of Medicine, University of Wisconsin-Madison

Adult children of persons with Alzheimer’s disease are at increased risk of developing Alzheimer’s disease because of hereditary, environmental, and health risk factors shared with affected parents. The Wisconsin Registry for Alzheimer’s Prevention (WRAP) has completed baseline assessments on 452 middle-aged persons (mean = 53 years) who have at least 1 parent with AD. Forty-five percent had 1 or more apolipoprotein (APOE) 4 alleles. There were few significant differences between 4 carriers and noncarriers in demographics, health, and lifestyle measures or in neuropsychological performance. The high percentage of WRAP participants who are carriers of APOE 4 underscores their increased risk for developing Alzheimer’s disease, but the absence of differences related to APOE status and high mean scores on cognitive tests suggests that the APOE 4 gene has yet to have a clinical impact on cognitive functioning. The WRAP cohort may be a valuable group to follow prospectively to characterize the nature of cognitive change in relation to risk factors and to identify underlying preclinical neurobiological changes.

Key Words: Alzheimer’s disease • family history • cognition • apolipoprotein

Journal of Geriatric Psychiatry and Neurology, Vol. 18, No. 4, 245-249 (2005)
DOI: 10.1177/0891988705281882


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				G. Xu, D. G. Mclaren, M. L. Ries, M. E. Fitzgerald, B. B. Bendlin, H. A. Rowley, M. A. Sager, C. Atwood, S. Asthana, and S. C. Johnson The influence of parental history of Alzheimer's disease and apolipoprotein E {varepsilon}4 on the BOLD signal during recognition memory Brain, February 1, 2009; 132(2): 383 - 391. [Abstract] [Full Text] [PDF]

				S. C. Johnson, M. L. Ries, T. M. Hess, C. M. Carlsson, C. E. Gleason, A. L. Alexander, H. A. Rowley, S. Asthana, and M. A. Sager Effect of Alzheimer Disease Risk on Brain Function During Self-appraisal in Healthy Middle-aged Adults Arch Gen Psychiatry, October 1, 2007; 64(10): 1163 - 1171. [Abstract] [Full Text] [PDF]

				T. Sunderland, H. Hampel, M. Takeda, K. T. Putnam, and R. M. Cohen Biomarkers in the Diagnosis of Alzheimer's Disease: Are We Ready? J Geriatr Psychiatry Neurol, September 1, 2006; 19(3): 172 - 179. [Abstract] [PDF]

				S. C. Johnson, T. W. Schmitz, M. A. Trivedi, M. L. Ries, B. M. Torgerson, C. M. Carlsson, S. Asthana, B. P. Hermann, and M. A. Sager The influence of Alzheimer disease family history and apolipoprotein E epsilon4 on mesial temporal lobe activation. J. Neurosci., May 31, 2006; 26(22): 6069 - 6076. [Abstract] [Full Text] [PDF]

				L. F. Jarvik and D. Blazer Children of Alzheimer Patients: An Overview J Geriatr Psychiatry Neurol, December 1, 2005; 18(4): 181 - 186. [PDF]